Abstract
Prostate cancer is the most common internal malignancy in US men. Approximately, 1 out of 7 men will be diagnosed with prostate cancer and approximately 1 out of 35 men die of prostate cancer annually, making it the second leading cause of cancer death in the USA. The decision to perform screening should be individualized and based on the patient’s values and preferences. Estimates of life expectancy are the main determinants of the primary treatment modality for prostate cancer and the optimal treatment requires assessment of risk (i.e., likelihood of cancer progression after treatment or need for adjuvant treatment). Gleason score from the prostate biopsy specimen, prostate specific antigen, digital rectal examination, and imaging are used to determine the clinical stage of prostate cancer.
| Original language | English |
|---|---|
| Title of host publication | Oncology |
| Publisher | wiley |
| Pages | 23-31 |
| Number of pages | 9 |
| ISBN (Electronic) | 9781119189596 |
| ISBN (Print) | 9781119189558 |
| DOIs | |
| State | Published - 30 Aug 2019 |
Keywords
- Active surveillance
- Gleason score
- Prostate cancer
- Prostate specific antigen (PSA)
- Radiation therapy
- Robotic prostatectomy
- Screening